Pharmacologic unmasking of epigenetically silenced genes in breast cancer

Clinical Cancer Research

Volumn 15, Issue 4, 2009, Pages 1184-1191

  Ostrow, Kimberly Laskie ^a   Park, Hannah Lui ^a   Hoque, Mohammad Obaidul ^a   Kim, Myoung Sook ^a   Liu, Junwei ^a   Argani, Pedram ^b   Westra, William ^b   Van Criekinge, Wim ^c   Sidransky, David ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c OncoMethylome Sciences SA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BISULFITE; CARRIER PROTEIN; FK 506 BINDING PROTEIN; KIF1A PROTEIN, HUMAN; KINESIN; MAL PROTEIN, T CELL; MAL PROTEIN, T-CELL; MYELIN PROTEIN; NERVE GROWTH FACTOR; PROTEOLIPID; TACROLIMUS BINDING PROTEIN 4; VGF PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CELL; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DNA SEQUENCE; EPIGENETICS; FEMALE; FISHER EXACT TEST; FKBP4 GENE; GENE; GENE IDENTIFICATION; GENE SILENCING; HUMAN; HUMAN CELL; KIF1A GENE; MAL GENE; METHYLATION; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; OGDHL GENE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; UPREGULATION; VGF GENE; BREAST TUMOR; DNA METHYLATION; DNA MICROARRAY; GENETIC EPIGENESIS; GENETICS; MIDDLE AGED; PROMOTER REGION; TUMOR CELL LINE;

ADULT; AGED; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE SILENCING; HUMANS; KINESIN; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; MYELIN PROTEINS; NERVE GROWTH FACTORS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS, GENETIC; PROTEOLIPIDS; TACROLIMUS BINDING PROTEINS;

EID: 63149192776     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1304     Document Type: Article

References (45)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30.
2. Elmore JG, Barton MB, Moceri VM, Polk S, Arena PJ, Fletcher SW. Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med 1998;338:1089-96.
3. Elmore JG, Wells CK, Howard DH. Does diagnostic accuracy in mammography depend on radiologists' experience? J Womens Health 1998; 7:443-9.
4. Hamill J, Campbell ID, Mayall F, Bartlett AS, Darlington A. Improved breast cytology results with near patient FNA diagnosis. Acta Cytol 2002;46:19-24.
5. Dulaimi E, Hillinck J, Ibanez de Caceres I, Al-Saleem T, Cairns P. Tumor suppressor gene promoter hyper-methylation in serum of breast cancer patients. Clin Cancer Res 2004;10:6189-93.
6. Hoque MO, Feng Q.Toure P, et al. Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. J Clin Oncol 2006;24: 4262-9.
7. Krassenstein R, Sauter E, Dulaimi E, et al. Detection of breast cancer in nipple aspirate fluid by CpG island hypermethylation. Clin Cancer Res 2004;10:28-32.
8. Taback B, Giuliano AE, Lai R, et al. Epigenetic analysis of body fluids and tumor tissues: application of a comprehensive molecular assessment for early-stage breast cancer patients. Ann N Y Acad Sci 2006; 1075:211-21.
9. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
10. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998;72:141-96.
11. Bird A. The essentials of DNA methylation. Cell 1992;70:5-8.
12. Leonhardt H, Cardoso MC. DNA methylation, nuclear structure, gene expression and cancer. J Cell Biochem Suppl 2000;Suppl 35:78-83.
13. Esteller M. Cancer epigenetics: DNA methylation and chromatin alterations in human cancer. Adv Exp Med Biol 2003;532:39-49.
14. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001;61:3225-9.
15. Dammann R. Yang G, Pfeifer GP Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res 2001;61:3105-9.
16. Herman JG, Umar A, Polyak K, et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci USA1998;95:6870-5.
17. Umbricht CB, Evron E, Gabrielson E, Ferguson A, Marks J, Sukumar S. Hypermethylation of 14-3-3σ (stratifin) is an early event in breast cancer. Oncogene 2001;20:3348-53.
18. Belinsky SA, Nikula KJ, Palmisano WA, et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A 1998:95:11891-6.
19. Esteller M, Sparks A.Toyota M, et al. Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer. Cancer Res 2000;60:4366-71.
20. Agrawal A, Murphy RF, Agrawal DK. DNA methylation in breast and colorectal cancers. Mod Pathol 2007;20:711-21.
21. Miyamoto K, Fukutomi T, Akashi-Tanaka S, et al. Identification of 20 genes aberrantly methylated in human breast cancers. Int J Cancer 2005;116: 407-14.
22. Esteller M. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum Mol Genet 2007;16 Spec No1:R50-9.
23. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet 2007; 8:286-98.
24. Hoque MO, Kim M, Ostrow K, et al. Genome-wide promoter analysis uncovers protions of the cancer "methylome" in primary tumors and cell lines. Cancer Res 2008;68:2661-70.
25. Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004;5:R80.
26. Hoque MO, Lee CC, Cairns P, Schoenberg M, Sidransky D. Genome-wide genetic characterization of bladder cancer: a comparison of high-density single-nucleotide polymorphism arrays and PCR-based microsatellite analysis. Cancer Res 2003:63: 2216-22.
27. Hoque MO, Begum S, Topaloglu O, et al. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J Natl Cancer Inst 2006;98:996-1004.
28. Hoque MO, Topaloglu O, Begum S, et al. Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. J Clin Oncol 2005;23:6569-75.
29. TokumaruY, Harden SV, Sun Dl, Yamashita K, Epstein Jl, Sidransky D. Optimal use of a panel of methylation markers with GSTP1 hypermethylation in the diagnosis of prostate adenocarcinoma. Clin Cancer Res 2004; 10:5518-22.
30. Tokumaru Y, Yamashita K, Osada M, et al. Inverse correlation between cyclin A1 hypermethylation and p53 mutation in head and neck cancer identified by reversal of epigenetic silencing. Cancer Res 2004;64: 5982-7.
31. Yamashita K, Upadhyay S, Osada M, et al. Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2002;2:485-95.
32. Liu J, Nagpal J, Jeronimo C, et al. Hypermethylation of MCAM gene is associated with advanced tumor stage in prostate caner. Prostate 2008;68:418-26.
33. Kazemi-Noureini S, Colonna-Romano S, Ziaee AA, et al. Differential gene expression between squamous cell carcinoma of esophagus and its normal epithelium; altered pattern of mal, akr1c2, and rablla expression. World J Gastroenterol 2004;10:1716-21.
34. Lind GE, Ahlquistt Lottie RA. DNA hypermethylation of MAL: a promising diagnostic biomarker for colorectal tumors. Gastroenterology 2007;132:1631-2; author reply 1632.
35. Mimori K, Shiraishi T, Mashino K, et al. MAL gene expression in esophageal cancer suppresses motility, invasion and tumorigenicity and enhances apoptosis through the Fas pathway. Oncogene 2003;22: 3463-71.
36. Cheung-Flynn J, PrapapanichV, Cox MB, Riggs DL, Suarez-Quian C, Smith DF. Physiological role for the cochaperone FKBP52 in androgen receptor signaling. Mol Endocrinol 2005;19:1654-66.
37. Lin JF, Xu J, Tian HY, et al. Identification of candidate prostate cancer biomarkers in prostate needle biopsy specimens using proteomic analysis. Int J Cancer 2007;121:2596-605.
38. Ward BK, Mark RJ, Ingram DM, Minchin RF, Ratajczak T. Expression of the estrogen receptor-associated immunophilins, cyclophilin 40 and FKBP52, in breast cancer. Breast Cancer ResTreat1999;58:267-80.
39. Kumar P, Mark PJ. Ward BK, Minchin RF, Ratajczak T. Estradiol-regulated expression of the immunophilins cyclophilin 40 and FKBP52 in MCF-7 breast cancer cells. Biochem Biophys Res Commun 2001;284: 219-25.
40. Hernandez-Vargas H, Rodriguez-Pinilla SM, Julian-Tendero M, et al. Gene expression profiling of breast cancer cells in response to gemcitabine: NF-κB pathway activation as a potential mechanism of resistance. Breast Cancer ResTreat 2007;102:157-72.
41. Neer EJ, Schmidt CJ, Nambudripad R, Smith TF. The ancient regulatory-protein family of WD-repeat proteins. Nature1994;371:297-300.
42. Li D, Roberts R. WD-repeat proteins: structure characteristics, biological function, and their involvement in human diseases. Cell Mol Life Sci 2001;58: 2085-97.
43. Belinsky SA, Liechty KC, Gentry FD, et al. Promoter hypermethylation of multiple genes in sputum precedes lung cancer incidence in a high-risk cohort. Cancer Res 2006;66:3338-44.
44. Hsu HS, Chen TP, Hung CH, et al. Characterization of a multiple epigenetic marker panel for lung cancer detection and risk assessment in plasma. Cancer 2007;110:2019-26.
45. Lo YM. Circulating nucleic acids in plasma and serum: an overview. Ann N YAcad Sci 2001;945:1-7.